L. Lafrance

发表

Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.

Maxwell D Cummings, B. Tomczuk, J. Spurlino, 2005, Journal of medicinal chemistry.

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations

Yan Liu, Gopinath Ganji, Ryan G. Kruger, 2012, Nature.

EZH 2 inhibition as a therapeutic strategy for lymphoma with EZH 2-activating mutations

G. Ganji, A. P. Graves, L. Lafrance, 2012 .

Development and Validation of Reagents and Assays for EZH2 Peptide and Nucleosome High-Throughput Screens

S. Thrall, G. Hofmann, L. Lafrance, 2012, Journal of biomolecular screening.

Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo

D. Parks, Tianbao Lu, J. Marugan, 2006, Molecular Cancer Therapeutics.

1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.

Maxwell D Cummings, D. Parks, Tianbao Lu, 2005, Bioorganic & medicinal chemistry letters.

Design, Synthesis, and Biological Evaluation of Novel Potent and Selective αvβ3/αvβ5 Integrin Dual Inhibitors with Improved Bioavailability. Selection of the Molecular Core

B. Tomczuk, Tianbao Lu, J. Marugan, 2005 .

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase.

G. Warren, R. Copeland, T. J. Lansing, 2008, Journal of medicinal chemistry.

Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.

A. P. Graves, L. Lafrance, Christine Thompson, 2012, ACS medicinal chemistry letters.

Synthesis and biological activity of dynorphin-(1-13) and analogs substituted in positions 8 and 10.

L. Lafrance, M. Dumont, S. Lemaire, 2009, International journal of peptide and protein research.

Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.

Sharad Verma, Kristin K. Brown, Anthony E Choudhry, 2010, Bioorganic & medicinal chemistry letters.

High-Throughput Screens Development and Validation of Reagents and Assays for EZH 2 Peptide and Nucleosome

Sharon, S. Thrall, G. Hofmann, 2012 .

Substituted 1,4‐Benzodiazepine‐2,5‐diones as α‐Helix Mimetic Antagonists of the HDM2‐p53 Protein–Protein Interaction

Maxwell D Cummings, D. Parks, Tianbao Lu, 2006, Chemical biology & drug design.

Discovery of Proline-Based p300/CBP Inhibitors Using DNA-Encoded Library Technology in Combination with High-Throughput Screening.

Douglas W. Thomson, Zhengrong Zhu, J. Boehm, 2022, Journal of medicinal chemistry.

Abstract 4700: A novel selective EZH2 inhibitor exhibits anti-tumor activity in lymphoma with EZH2 activating mutations

G. Ganji, L. Lafrance, Christine Thompson, 2012 .

Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.

Maxwell D Cummings, D. Parks, Tianbao Lu, 2006, Bioorganic & medicinal chemistry letters.

Cell-Based Drug Discovery: Identification and Optimization of Small Molecules that Reduce c-MYC Protein Levels in Cells.

J. F. Mack, L. Lafrance, R. Rivero, 2021, Journal of medicinal chemistry.

A facile method for the synthesis of substituted pyrazolo[3,4-c]pyridines

L. Lafrance, S. Verma, 2009 .